Search
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … effective treatments for VMS by relieving symptoms in as many as 95% of menopausal women.
Clomipramine
go.drugbank.com/drugs/DB01242ApprovedInvestigationalVet approvedThey contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. … See toxicity section below for a complete listing of side effects.
Categories: Antidepressive Agents Indicated for Depression, Non-Selective Monoamine Reuptake InhibitorsSynonyms: 3-(3-chloro-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine, 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamineCorticorelin ovine triflutate
go.drugbank.com/drugs/DB09067ApprovedIt provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ectopic ACTH syndrome (an ectopic source of ACTH excess). … However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient is diagnosed with ectopic ACTH syndrome.
Categories: Tests for Pituitary FunctionDengue virus serotype 1
go.drugbank.com/drugs/DB22664Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.
Isopropyl myristate
go.drugbank.com/drugs/DB13966Approved[A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966]. … Isopropyl myristate is a moisturizer with polar characteristics used in cosmetics and topical medical preparations to ameliorate the skin absorption.
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigationalMantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … [L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma
Fencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile. … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsBenzonatate
go.drugbank.com/drugs/DB00868Approved[L11193] Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and overdose, especially in children.[A189513] … [A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and pleura involved in the cough reflex.
Categories: Non-narcotic AntitussiveSynonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate, p-butylaminobenzoic acid ω-O-methylnonaethyleneglycol esterBuspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalIt has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate. … Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Co BuspironeFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … Fitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety.